Bal Pharma Ltd
Bal Pharma Ltd (BALPHARMA) last reported results for the quarter ended Jun 2026, with sales of ₹88.62 crore and net profit of ₹1.13 crore. The next scheduled event is a record date on 30 Oct 2026. The stock last traded at ₹102, a market capitalisation of ₹163 crore, on a P/E of 22.7. Over the past 52 weeks the stock has ranged between ₹59.7 and ₹125. Figures are as of 6 Oct 2026 and are not real time.
Bal Pharma Ltd share price and key metrics
- Current price
- ₹102
- Market cap
- ₹163 cr
- Stock P/E
- 22.7
- Book value
- ₹51.6
- ROE
- 7.87%
- ROCE
- 9.69%
- Dividend yield
- 1.17%
- 52w high / low
- 125/59.7
Metrics as of 6 Oct 2026. Not real time.
Track Bal Pharma Ltd
Cruxal reads every Bal Pharma Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Bal Pharma Ltd growth and returns
- 10 Years
- 5%
- 5 Years
- 4%
- 3 Years
- 1%
- TTM
- 14%
- 10 Years
- 16%
- 5 Years
- 6%
- 3 Years
- 35%
- TTM
- 1%
- 10 Years
- -1%
- 5 Years
- 0%
- 3 Years
- 4%
- 1 Year
- 28%
- 10 Years
- 5%
- 5 Years
- 8%
- 3 Years
- 9%
- Last Year
- 8%
Bal Pharma Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹88.62 cr, up 34.5% from ₹65.87 cr a year earlier. Net profit was ₹1.13 cr, up 438.1% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 73.69 | 73.15 | 81.88 | 65.87 | 74.02 | 87.69 | 84.08 | 88.62 |
| Expenses | 66 | 65.4 | 74.24 | 59.81 | 68.29 | 78.15 | 73.5 | 80.67 |
| Operating profit | 7.69 | 7.75 | 7.64 | 6.06 | 5.73 | 9.54 | 10.58 | 7.95 |
| OPM % | 10.44% | 10.59% | 9.33% | 9.20% | 7.74% | 10.88% | 12.58% | 8.97% |
| Other income | -0.2 | 0.51 | 1.08 | 0.72 | 1.12 | 0.33 | -0.24 | 0.44 |
| Interest | 3.65 | 5.01 | 3.95 | 4.05 | 3.86 | 4.85 | 4.06 | 4.47 |
| Depreciation | 2.48 | 2.69 | 2.18 | 2.52 | 2.27 | 3.23 | 3.06 | 2.78 |
| Profit before tax | 1.36 | 0.56 | 2.59 | 0.21 | 0.72 | 1.79 | 3.22 | 1.14 |
| Tax % | 23.53% | 7.14% | -108.88% | 0.00% | 0.00% | 0.00% | -12.11% | 0.00% |
| Net profit | 1.04 | 0.52 | 5.41 | 0.21 | 0.72 | 1.79 | 3.6 | 1.13 |
| EPS (₹) | 0.65 | 0.30 | 3.41 | 0.13 | 0.45 | 1.12 | 2.25 | 0.70 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Bal Pharma Ltd annual results
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 229 | 211 | 225 | 171 | 251 | 281 | 304 | 339 | 303 | 312 | 334 |
| Operating profit | 15 | 17 | 18 | 5 | 25 | 24 | 25 | 31 | 30 | 32 | 34 |
| OPM % | 6% | 8% | 8% | 2.9% | 10% | 9% | 8% | 9% | 10% | 10% | 10% |
| Net profit | -0 | 0 | 2 | -13 | 5 | 6 | 3 | 7 | 7 | 6 | 7 |
| EPS (₹) | 1.24 | 1.96 | 2.67 | -8.62 | 3.20 | 3.78 | 1.64 | 4.68 | 4.53 | 3.94 | 4.52 |
TTM is the trailing twelve months to the most recent quarter.
Bal Pharma Ltd balance sheet
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity capital | 14 | 14 | 14 | 14 | 15 | 15 | 16 | 16 | 16 | 16 |
| Reserves | 48 | 51 | 52 | 38 | 39 | 44 | 48 | 56 | 62 | 66 |
| Borrowings | 93 | 110 | 124 | 118 | 110 | 104 | 131 | 140 | 150 | 160 |
| Other liabilities | 78 | 86 | 71 | 68 | 76 | 98 | 116 | 108 | 108 | 134 |
| Total liabilities | 233 | 260 | 261 | 238 | 240 | 261 | 311 | 320 | 336 | 376 |
| Fixed assets | 60 | 71 | 70 | 71 | 69 | 67 | 76 | 80 | 87 | 94 |
| CWIP | 2 | 0 | 4 | 3 | 0 | 2 | 0 | 0 | 3 | 7 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 7 | 2 | 2 |
| Other assets | 172 | 188 | 187 | 164 | 172 | 192 | 235 | 233 | 244 | 272 |
| Total assets | 233 | 260 | 261 | 238 | 240 | 261 | 311 | 320 | 336 | 376 |
As reported by the company. Total assets equal total liabilities by construction.
Bal Pharma Ltd cash flow
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 6 | 1 | 8 | 23 | 22 | 27 | -2 | 23 | 20 | 30 |
| Cash from investing | -8 | -4 | -8 | -5 | -6 | -9 | -22 | -19 | -15 | -21 |
| Cash from financing | -6 | 4 | 0 | -20 | -17 | -17 | 24 | -1 | -8 | -10 |
| Net cash flow | -8 | 1 | -0 | -2 | 0 | 0 | 0 | 3 | -2 | 0 |
| Free cash flow | -2 | -3 | -1 | 18 | 19 | 18 | -16 | 12 | 2 | 8 |
| CFO / operating profit | 52% | 11% | 57% | 465% | 91% | 117% | -4% | 88% | 75% | 95% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
Bal Pharma Ltd operating ratios
| Per year | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % | 8% | 8% | 7% | -0% | 10% | 12% | 10% | 12% | 10% | 10% |
| Debtor days | 99 | 111 | 105 | 106 | 98 | 98 | 113 | 107 | 111 | 110 |
| Inventory days | 172 | 240 | 217 | 292 | 146 | 162 | 207 | 167 | 238 | 269 |
| Days payable | 171 | 182 | 147 | 167 | 114 | 143 | 167 | 147 | 189 | 206 |
| Cash conversion cycle | 100 | 168 | 175 | 231 | 130 | 117 | 153 | 127 | 161 | 173 |
| Working capital days | 26 | 45 | 25 | -11 | 11 | 18 | 13 | 12 | 6 | 7 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
Bal Pharma Ltd shareholding pattern
Promoters held 50.87% at Jun 2026, broadly unchanged since Jun 2025. FIIs 0.15%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 50.87% | 50.87% | 50.87% | 50.87% | 50.87% | 50.87% | 50.87% | 50.87% |
| FIIs | 0.13% | 0.14% | 0.14% | 0.15% | 0.23% | 0.14% | 0.14% | 0.15% |
| Public | 49.01% | 49.00% | 49.01% | 48.99% | 48.91% | 49.01% | 49.01% | 48.99% |
| No. of shareholders | 16,007 | 15,667 | 15,723 | 15,826 | 15,774 | 15,520 | 15,214 | 14,974 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Upcoming Bal Pharma Ltd events
The next scheduled event is a record date on 30 Oct 2026.
- Record dateClaim unclaimed dividends and shares before transfer to IEPF
See the full results calendar for every Indian company reporting in the next 30 days.
Bal Pharma Ltd corporate filings
- Compliance Certificate under Reg 74 (5) of SEBI (DP) Regulation 2018 for the quarter ended 30th September 2026Company Updatelow impact
- Bal Pharma Limited Announces Board Re-designations and Committee ReconstitutionCompany Updatelow impact
Cruxal's analysis: Bal Pharma Limited has informed the exchanges of a change in the designations of two…
Read the full analysis - Bal Pharma Limited Announces Successful Conclusion of 39th AGM and Dividend ApprovalAGM/EGMlow impact
Cruxal's analysis: Bal Pharma Limited has successfully concluded its 39th Annual General Meeting held on…
Read the full analysis - Intimation of Closure of Trading Window from 01st October 2026 till 48 hours after the declaration of the financial result of the Company for the quarter ended 30th September 2026 (Q2)Insider Trading / SASTlow impact
- Bal Pharma Limited concludes 39th Annual General Meeting; approves dividend of INR 1.20 per shareAGM/EGMlow impact
Cruxal's analysis: Bal Pharma Limited has successfully concluded its 39th Annual General Meeting, where…
Read the full analysis - Bal Pharma Ltd issues clarification regarding recent stock price movementCompany Updatelow impact
Cruxal's analysis: Bal Pharma Ltd has submitted a formal clarification to the stock exchange regarding the…
Read the full analysis - Bal Pharma Limited allots 10 lakh convertible warrants to promoter at INR 84 per share, raising INR 8.40 croreCompany Updatehigh impact
Cruxal's analysis: Bal Pharma Limited has completed the allotment of 10 lakh convertible warrants to its…
Read the full analysis - Bal Pharma Limited announces record date of September 17, 2026, for final dividend of INR 1.20 per shareCorp. Actionlow impact
Cruxal's analysis: Bal Pharma Limited has officially declared Thursday, September 17, 2026, as the record…
Read the full analysis - Bal Pharma Limited releases Annual Report for the financial year 2025-26Otherslow impact
Cruxal's analysis: Bal Pharma Limited has filed its Annual Report for the financial year 2026. The report…
Read the full analysis - Bal Pharma Limited Announces 39th AGM and Declares Final Dividend of INR 1.20 per ShareAGM/EGMlow impact
Cruxal's analysis: Bal Pharma Limited has scheduled its 39th Annual General Meeting for September 24, 2026…
Read the full analysis - Bal Pharma Limited schedules 39th Annual General Meeting for September 24, 2026, and sets record date for final dividendAGM/EGMlow impact
Cruxal's analysis: Bal Pharma Limited has formally announced its 39th Annual General Meeting to be held on…
Read the full analysis - Bal Pharma Limited clarifies 18-month utilization timeline for preferential issue proceedsCompany Updatelow impact
Cruxal's analysis: Bal Pharma Limited has issued a clarification regarding its preferential issue of…
Read the full analysis - Bal Pharma Limited Announces Q1 FY2026-27 Financial Results and IEPF Share Transfer NoticeCompany Updatelow impact
Cruxal's analysis: Bal Pharma Limited has released its unaudited standalone and consolidated financial…
Read the full analysis - Bal Pharma Limited reports Q1 FY2027 standalone net profit of 1.16 crore, showing YoY growthResulthigh impact
Cruxal's analysis: Bal Pharma Limited reported standalone revenue from operations of 88.43 crore for the…
Read the full analysis - Bal Pharma Reports Q1 FY27 Results, Announces Philippines JV and Promoter Warrant AllotmentBoard Meetinghigh impact
Cruxal's analysis: Bal Pharma Limited reported Q1 FY27 standalone revenue of 88.43 crore and a net profit of…
Read the full analysis - Bal Pharma Limited shareholders approve preferential issue of 10 lakh warrants to promotersAGM/EGMmedium impact
Cruxal's analysis: Bal Pharma Limited has received shareholder approval via postal ballot for the issuance…
Read the full analysis - Bal Pharma Limited shareholders approve preferential issue of 10 lakh warrants to promotersAGM/EGMmedium impact
Cruxal's analysis: Bal Pharma Limited has received shareholder approval via postal ballot for the…
Read the full analysis - Bal Pharma Limited schedules Board Meeting for August 12, 2026, to approve Q1 2026-27 financial resultsBoard Meetinglow impact
Cruxal's analysis: Bal Pharma Limited has issued a formal intimation regarding a Board of Directors meeting…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.